Search results
Results From The WOW.Com Content Network
A coalition of attorneys general from nearly every state filed a massive lawsuit Wednesday charging 26 generic drug companies and 10 executives of conspiring to reduce competition and raise prices.
Medicare fraud, kickbacks Zocor, Vioxx, Pepsid: False Claims Act, Medicaid Rebate Statute 2007 Purdue Pharma [15] $601 million Off-label promotion Oxycontin: False Claims Act 2010 Allergan [16] $600 million Off-label promotion Botox: False Claims Act, FDCA 2010 AstraZeneca [17] $520 million Off-label promotion, kickbacks Seroquel: False Claims ...
The ability to allow Medicare to negotiate drug prices was included in the Inflation Reduction Act passed by Congress in 2022. The act also sets a $2,000 price cap on out-of-pocket drug expenses ...
Prescription drug list prices in the United States continually are among the highest in the world. [1] [2] The high cost of prescription drugs became a major topic of discussion in the 21st century, leading up to the American health care reform debate of 2009, and received renewed attention in 2015.
The lawsuit claims the Khubani’s infringed on the Happy Product’s “Flippy” patent in 2019 when they began manufacturing and selling a similar item dubbed the “Pillow Pad.”
United States of America v. Regenerative Sciences, LLC, 741 F.3d 1314 (D.C. Cir. 2014), [1] was a decision in the United States Court of Appeals for the District of Columbia Circuit filed on February 4, 2014 concerning more than minimally manipulated cell therapies and whether they are considered part of medical practice or a drug, the latter subjecting it to regulation under the Food and Drug ...
Several headwinds are impacting the company, including generic competition for its blockbuster drug Stelara, the ongoing talc lawsuit (which could see a final decision in the first half of the ...
After loss of exclusivity and generic launch the originator brand normally continues to hold at least some market share as either some doctors continue to prescribe the brand or as the originator equalises sales prices against the generic. [27] [28] Generic, brand and reimbursement (drug tariff) price decay